Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 409306 for Relapse Prevention in Schizophrenia
NCT03351244Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2017
- Primary completion
- Mar 2021
- Countries
- 7
01
Overview
A Phase 2 trial of osoresnontrine in schizophrenia, sponsored by Boehringer Ingelheim. Started Dec 2017; status: terminated.
02
Drugs
osoresnontrine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03351244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03351244.